COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings
NCT04371835 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 596
Last updated 2022-03-18
Summary
COHIVE is an observational cohort nested in four antiretroviral therapy research studies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229). COHIVE will include participants who are possible COVID-19 cases with symptoms or confirmed COVID-19 cases, and participants who agree to have a serology testing for SARS-CoV-2 regardless of COVID-19 history.
Conditions
- HIV-infection/Aids
- Coronavirus Infection
Sponsors & Collaborators
-
University of Witwatersrand, South Africa
collaborator OTHER -
University of Liverpool
collaborator OTHER -
Université Montpellier
collaborator OTHER -
UNITAID
collaborator OTHER -
ViiV Healthcare
collaborator INDUSTRY -
Kirby Institute
lead OTHER_GOV
Principal Investigators
-
Alexandra Calmy, MD, PhD · University Hospital, Geneva
-
Eric Delaporte, MD, PhD · IRD, Inserm, University of Montpellier
-
Saye Khoo, MD, PhD · University of Liverpool
-
Emmanuelle Papot, MD · Kirby Institute
-
Mark Polizzotto, MD, PhD · Kirby Institute
-
Francois WD Venter, MD · Wits Reproductive Health and HIV Institute
-
Joana Woods, MD · Wits Reproductive Health and HIV Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-12
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- Argentina
- Brazil
- Cameroon
- India
- Malaysia
- Nigeria
- South Africa
- Thailand
- Uganda
- Zimbabwe
Study Locations
More Related Trials
-
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
NCT04880785 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
NCT00100048 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
NCT02397096 ·Status: COMPLETED ·Phase: PHASE3
-
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
NCT01565889 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
NCT01797445 ·Status: COMPLETED ·Phase: PHASE3
-
Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study
NCT02211482 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
NCT00046176 ·Status: COMPLETED ·Phase: PHASE3
-
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
NCT00127959 ·Status: COMPLETED ·Phase: PHASE4
-
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)
NCT03446573 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
NCT00002218 ·Status: COMPLETED ·Phase: PHASE1
-
Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week
NCT04867083 ·Status: UNKNOWN ·Phase: PHASE3
-
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
NCT04507321 ·Status: COMPLETED ·Phase: PHASE1
-
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
NCT06497465 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
NCT00002199 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
NCT02384395 ·Status: COMPLETED ·Phase: NA
-
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
NCT00053638 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
NCT00105157 ·Status: COMPLETED ·Phase: PHASE2
-
Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)
NCT03351699 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
NCT02174159 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
NCT00004852 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
NCT05493969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal
NCT00100568 ·Status: COMPLETED ·Phase: NA
-
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
NCT00199979 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
NCT02603107 ·Status: COMPLETED ·Phase: PHASE3